The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction

Aims Endothelin-1 (ET-1) has been implicated in the pathophysiology of a number of cardiovascular diseases for which endothelin receptor antagonists are currently under clinical development. We have previously reported that systemic administration of the combined endothelin A/B receptor antagonist,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ferro, C. J., Haynes, W. G., Johnston, N. R., Lomax, C. C., Newby, D. E., Webb, D. J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 1997
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2042857/
https://ncbi.nlm.nih.gov/pubmed/9354313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.1997.00595.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak